Table 1.
detailing the characteristics of the included studies
| First Author, Year | Study design | Language | Total number of patients | Number of patients | Age | Gender (F:M) |
Kellgren-Lawrence Score (I:II:III:IV) |
Follow-up period | Outcomes reported | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRP + HA | PRP | PRP + HA | PRP | PRP + HA | PRP | PRP + HA | PRP | ||||||
| Ding, 2017 [12] | RCT | Chinese | 47 | 27 | 20 | 56.75 ± 9.54 | 62.11 ± 12.5 | 18:2 | 19:8 | 9:6:5:0 | 10:11:6:0 | 6 months | VAS, WOMAC, Lequesne |
| Zhao, 2018 [45] | RCT | Chinese | 124 | 62 | 62 | 55.73 ± 7.18 | 56.32 ± 8.13 | 27:35 | 25:37 | – | – | 5 weeks | VAS, JOA |
| Ke, 2016 [22] | RCT | Chinese | 150 | 50 | 50 | 57.80 ± 6.90 | 59.30 ± 7.10 | 25:25 | 26:24 | 5:11:20:14 | 6:12:20:12 | 12 months | WOMAC, IKDC, Lequesne |
| Guo, 2018 [17] | RCT | Chinese | 126 | 63 | 63 | 61.00 ± 10.00 | 61.00 ± 10.00 | 18:45 | 12:51 | 17:28:18:0 | 15:31:17:0 | 12 months | VAS, WOMAC |
| Abate, 2015 [1] | Retrospective cohort | English | 80 | 40 | 40 | 56.70 ± 11.20 | 60.90 ± 9.00 | 9:31 | 19:21 | 0:23:17:0 | 0:19:21:0 | 6 months | VAS, KOOS |
| Guo, 2016 [18] | Retrospective cohort | English | 126 | 63 | 63 | 61.20 ± 9.60 | 60.70 ± 10.10 | 45:18 | 51:12 | 17:28:18:0 | 15:31:17:0 | 12 months | VAS, WOMAC |
| Jacob, 2017 [21] | RCT | English | 51 | 20 | 31 | – | – | – | – | – | – | 6 months | VAS, IKDC |
| Yu, 2018 [42] | RCT | English | 360 | 104 | 96 | 46.50 ± 7.50 | 46.20 ± 8.60 | 46:50 | 54:50 | – | – | 12 months | WOMAC |
| Palco, 2021 [28] | Retrospective cohort | English | 51 | 28 | 23 | 62.71 ± 7.88 | 54.04 ± 10.4 | 16:12 | 11:12 | 0:8:20:0 | 0:10:13:0 | 12 months | VAS, KSS, KOOS |
| Sun, 2021 [37] | RCT | English | 78 | 39 | 39 | 60.6 ± 8.4 | 58.4 ± 8.1 | 18:21 | 22:17 | 0:39:0:0 | 0:39:0:0 | 6 months | VAS, WOMAC, Lequesne, SLS |